27 October 2025: Articles
Simultaneous Bilateral Methicillin-Resistant Staphylococcus aureus Infection After Total Knee Arthroplasty Successfully Treated with Continuous Local Antibiotic Perfusion: A Case Report
Unusual clinical course, Unusual or unexpected effect of treatment
Kohei Motono E 1, Tomoyuki Matsumoto E 1, Keisuke Oe E 1, Masanori Tsubosaka E 1, Naoki Nakano E 1, Tomoaki Fukui E 1, Yohei Kumabe E 1, Ryosuke Kuroda E 1DOI: 10.12659/AJCR.949779
Am J Case Rep 2025; 26:e949779
Abstract
BACKGROUND: Continuous local antibiotic perfusion (CLAP) delivers gentamicin continuously via a bone marrow needle and double-lumen tube in the infected area, taking advantage of the concentration-dependent bactericidal activity of gentamicin, and allowing even resistant bacteria to be inhibited at high local concentrations. CLAP has shown good outcomes in bone and soft-tissue infections. However, reports on its use for periprosthetic joint infection (PJI) after total knee arthroplasty are limited. Moreover, bilateral simultaneous methicillin-resistant Staphylococcus aureus (MRSA) infection following total knee arthroplasty is rare. We report the successful CLAP treatment of simultaneous bilateral MRSA infection after total knee arthroplasty.
CASE REPORT: A 69-year-old man with cerebral palsy presented with a 2-week history of gait difficulty and 3-day history of fever. At 12 and 9 months before presentation, he underwent left and right total knee arthroplasty, respectively. Both knees showed swelling, pain, and redness. The leukocyte count was 12 820/μL, and C-reactive protein level was 16.27 mg/dL. Bilateral aspiration revealed gram-positive cocci, confirming PJI, without implant loosening. We performed simultaneous debridement, irrigation, insert exchange, and CLAP on both knees. Intraoperative joint fluid cultures showed MRSA. Gentamicin was given intra-articularly for 14 days alongside intravenous vancomycin, which was continued for 31 days before switching to oral minocycline for 6 months. One year after surgery, the white blood cell count was 3400/µL, the C-reactive protein level was 0.08 mg/dL, and the range of motion was 0 to 130 degrees, with no recurrence of PJI.
CONCLUSIONS: CLAP represents a viable treatment option for PJI caused by MRSA after total knee arthroplasty.
Keywords: Arthroplasty, Replacement, Knee, Infection Control, Knee, Perfusion, Humans, Male, Aged, Methicillin-resistant Staphylococcus aureus, Staphylococcal Infections, Anti-Bacterial Agents, Prosthesis-Related Infections, Gentamicins
Introduction
Periprosthetic joint infection (PJI) is one of the most destructive complications following total knee arthroplasty [1–3]. Although guidelines for its management have been proposed, its treatment remains controversial and can require prolonged hospital stays, antibiotic therapy, and multiple surgical procedures [4]. PJI has serious adverse effects, including difficulties in performing daily activities. Most previous studies recommend treating chronic infection with a 2-stage revision arthroplasty or debridement, antibiotics, and implant retention (DAIR), with reported treatment success rates of 71.1% to 82.8% [5,6] and 9% to 62% [6,7], respectively. Recent studies have shown that the 5-year survival rate for patients with PJI is 87.3%, which is lower than that of patients with some types of cancer [8]. Treatment outcomes remain unsatisfactory, highlighting the urgent need to introduce new treatment methods to improve patient prognosis. Furthermore, simultaneous bilateral infections are rarely reported, resulting in a lack of guidance on determining appropriate treatment strategies.
In continuous local antibiotic perfusion (CLAP) therapy, a bone marrow needle and double-lumen tube are placed in the infected area, and an appropriate concentration of an antimicrobial agent is constantly perfused [9,10]. Soft-tissue and bone infections are managed using intra-soft tissue antibiotic perfusion and intra-medullary antibiotics perfusion, respectively [9–12]. CLAP therapy has shown good eradication outcomes in the treatment of bone and soft-tissue infections [9–12]. CLAP administered to the joint is referred to as intra-joint antibiotic perfusion (iJAP) [13]. Although this is specific to fungal infections after total hip arthroplasty, treatment outcomes using CLAP therapy, including iJAP, have been reported [14]. These results indicate the efficacy of CLAP in the treatment of PJI.
Two-stage exchange replacement surgery, the standard approach especially for chronic infection, would have required multiple surgeries and imposed physical and financial burdens on the patient [7]. On the other hand, DAIR is regarded as a patient-friendly approach, offering economic and physical advantages by preserving the implant through a single, minimally invasive surgical procedure [15]. Furthermore, although DAIR treatment for chronic infections is known to yield poorer outcomes in cases involving high-virulence organisms than in those involving low-virulence or culture-negative infections [15], the addition of CLAP may help to overcome this limitation.
We present the case of a 69-year-old patient with bilateral PJI who was successfully treated for implant retention and resolution of the PJI using DAIR combined with iJAP. To the best of our knowledge, this is the first report of simultaneous bilateral PJI treated in this manner. The successful combination of DAIR and iJAP in the treatment of chronic bilateral simultaneous infections caused by resistant bacteria suggests a new treatment method for such cases.
Case Report
A 69-year-old man with no history of febrile illness but with a history of cerebral palsy and end-stage osteoarthritis in both knees, who had total knee arthroplasty (left, 12 months earlier; right, 9 months earlier), was referred to our hospital. Ambulation was assisted with a walker prior to the onset of PJI. He noticed difficulty walking 2 weeks before presentation, and 3 days prior he developed a fever and worsening respiratory symptoms, prompting him to visit his previous doctor. At that time, the doctor performed a blood culture and detected gram-positive cocci, raising suspicion of PJI. Therefore, the patient was referred to our hospital.
Physical examination showed a 15-cm vertical surgical scar from the primary total knee arthroplasty, with bilateral swelling, warmth, effusion, and tender knee joints. The patient’s vital signs were as follows: heart rate, 86 beats per min; blood pressure, 157/71 mmHg; respiratory rate, 15 breaths per min; saturation without additional oxygen, 98%; and temperature, 38.2°C. Laboratory test results revealed a white blood cell count of 12 820/μL, C-reactive protein level of 16.27 mg/dL, and erythrocyte sedimentation rate of 70 mm/h. Plain radiographs revealed no radiolucency (Figure 1).
Based on the suspicion of infection, we performed joint aspiration. Approximately 20 mL of purulent exudate was aspirated from both the left and right knee joints, and gram-positive cocci were isolated from the joint fluid cultures. No uric acid crystals or pyrophosphate crystals were detected in the synovial fluid sample; however, an increase in the number of white blood cells and neutrophil ratio in the synovial fluid was observed. Therefore, based on the Musculoskeletal Infection Society diagnostic criteria, PJI was diagnosed and surgical intervention was performed.
Intraoperatively, pyogenic exudates and acute synovitis were observed in both knees, and methicillin-resistant
On day 14 after CLAP initiation, the 2 Salem Sump tubes and SB bags were removed. Local findings improved during the procedure, and the inflammatory response normalized on postoperative day 25. In combination with the systematic administration of antibiotics via CLAP, vancomycin was administered intravenously on the day of surgery and continued until postoperative day 31. Walking training began on postoperative day 51. Subsequently, oral minocycline was commenced and continued for 6 months. The patient was discharged on postoperative day 64, and the range of motion at that time was 0 degrees in extension and 130 degrees in flexion on both sides (Figure 3). He was able to walk with a walker when he was discharged from the hospital. After discharge, monthly laboratory tests, imaging, and physical examinations were performed, with no signs of infection observed. As a result, the patient remained symptom-free and without recurrence 1 year later. Given the complete resolution of symptoms and normalization of inflammatory markers, additional surgical treatment was deemed unnecessary.
Figure 4 shows the changes in white blood cell count and C-reactive protein levels from the time of hospital admission to the time of transfer to another hospital, as well as the treatment administered.
Discussion
In recent years, treatment methods for PJI have been established [16,17]. However, only 4 cases of bilateral simultaneous infection have been reported [18–21], and there is no standard treatment strategy. Furthermore, 1 of the 4 cases of bilateral MRSA infection was hematogenous infection [18], and there have been no reports of chronic infection. In general, MRSA infections are reported to be more difficult to treat than non-MRSA infections in terms of implant retention and postoperative knee function [22,23]. Considering these points, the present case report provides useful information, as the incidence of PJI in both knees caused by MRSA is quite low and typically difficult to treat. Notably, in the present case, good treatment results were achieved with a single surgery.
This case was classified as a chronic infection according to Tsukayama et al [24]. Two-stage revision surgery is considered the standard treatment for chronic infection without implant loosening [24]. In a case series involving DAIR and 2-stage revision for treatment of chronic infection due to MRSA, the reported treatment success rate for the initial surgery was 0% [22], and postoperative loss of knee function was likely [23]. The success rate of 2-stage revision surgery for MRSA-related infections is only 22.4% [25]. The success rate of treatment remains low regardless of the method used, making the present case is a rare example of the successful resolution of late-stage symptoms of chronic bilateral MRSA infection of the knee using a novel therapy.
The conventional 2-stage revision surgery, which involves removing the implant, placing an antibiotic-containing cement spacer, and then reinserting the implant in a second surgery, has several disadvantages. First, antibiotic-impregnated cement achieves high local antibiotic concentrations; however, these levels rapidly decline within a few days and fall below the minimal biofilm eradication concentration (MBEC) [26], which is the concentration required to destroy biofilms. This concentration has been shown to be 100 to 1000 times higher than that of the MIC, which is the lowest concentration required to inhibit bacterial growth [26,27]. Prolonged exposure to sub-MIC levels of antibiotics can promote the selection of multidrug-resistant organisms, which can form biofilms on the cement surface and compromise treatment outcomes. Second, the cement spacer is in place for a long period during which the knee joint cannot be moved [7], potentially limiting its range of motion. Third, the need for 2 operations, both with significant anesthetic and surgical risks [7], is a concern for patients. Therefore, as shown in this case report, a single operation to eradicate an infection is ideal for preserving knee function and reducing the occurrence of various complications.
CLAP therapy can continuously deliver concentrations of antibacterial drugs above the MBEC directly to an infected area. In addition, to prevent shortcuts in perfusion fluid in the joint and preserve range of motion, we introduced continuous passive motion during CLAP therapy. Depending on the local findings and laboratory test results, local antibiotics should be administered for 1 to 2 weeks before being terminated [11]. Only a single operation is required, unless the infection flares. We believe that CLAP therapy can compensate for the disadvantages of 2-stage revision surgery. Furthermore, the MBEC of gentamicin for staphylococci, including MRSA, is reported to be up to 256 times higher than the MIC. This suggests that gentamicin can achieve the required MBEC at a lower concentration [28]. Therefore, it is thought that even infections caused by resistant bacteria can be controlled with gentamicin treatment at concentrations exceeding the MBEC. As a result, the bilateral MRSA infection in our case was resolved with a single surgery. In chronic PJI, for which 2-stage revision surgery is usually recommended, it is noteworthy that CLAP was able to control the infection with a single-stage treatment.
Although we described the usefulness of CLAP therapy, this case present only a single case of late chronic infection. Therefore, the effectiveness of this therapy for all simultaneous bilateral total knee arthroplasty infections remains to be determined. Long-term follow-up and accumulation of more cases are needed.
Conclusions
We reported a case of simultaneous bilateral PJI after total knee arthroplasty caused by MRSA that was successfully treated with CLAP therapy in combination with DAIR. This surgical method, if successful, can reduce the number of surgeries required and reduce the associated financial and physical burdens. Therefore, CLAP may be a viable treatment option for PJI caused by MRSA after total knee arthroplasty. Continued follow-up and accumulation of cases will provide further evidence supporting the effectiveness of this surgical method.
Figures
Figure 1. Preoperative radiographs showing no evidence of radiolucency.
Figure 2. Postoperative radiograph (A) and diagram of the continuous local antibiotic perfusion (B).
Figure 3. Radiographs at the time of discharge showing (A) frontal image of the right knee; (B) lateral image of the right maximum extension; (C) lateral image of the right knee in maximum flexion; (D) lateral image of the left maximum extension; (E) lateral image of the left maximum flexion; and (F) frontal image of the left knee.
Figure 4. The C-reactive protein (CRP*) levels, white blood cell (WBC**) counts, and intervention (antibiotics and surgery) are shown. References
1. Jeys LM, Patel R, Jenkins T, The infected total knee replacement: The worst and unfortunately most frequent complication: Orthopaedics and Trauma, 2025; 39(1); 42-54
2. Lum ZC, Natsuhara KM, Shelton TJ, Mortality during total knee periprosthetic joint infection: J Arthroplasty, 2018; 33(12); 3783-88
3. Kurtz SM, Lau E, Schmier J, Infection burden for hip and knee arthroplasty in the United States: J Arthroplasty, 2008; 23(7); 984-91
4. Vasso M, Capasso L, Corona K, Periprosthetic knee infection: Treatment options: Orthop Rev (Pavia), 2022; 14(4); 37537
5. Tigani D, Trisolino G, Fosco M, Two-stage reimplantation for periprosthetic knee infection: Influence of host health status and infecting microorganism: Knee, 2013; 20(1); 9-18
6. Segawa H, Tsukayama DT, Kyle RF, Infection after total knee arthroplasty. A retrospective study of the treatment of eighty-one infections: J Bone Joint Surg Am, 1999; 81(10); 1434-45
7. Qasim SN, Swann A, Ashford R, The DAIR (debridement, antibiotics and implant retention) procedure for infected total knee replacement – a literature review: SICOT J, 2017; 3; 2
8. Zmistowski B, Karam JA, Durinka JB, Periprosthetic joint infection increases the risk of one-year mortality: J Bone Joint Surg Am, 2013; 95(24); 2177-84
9. Himeno D, Matsuura Y, Maruo A, Ohtori S, A novel treatment strategy using continuous local antibiotic perfusion: A case series study of a refractory infection caused by hypervirulent Klebsiella pneumoniae: J Orthop Sci, 2022; 27(1); 272-80
10. Maruo A, Oda T, Miya H, Intra-medullary antibiotics perfusion (iMAP) for the control of fracture-related infection early after osteosynthesis: J Orthop Surg (Hong Kong), 2021; 29(3); 23094990211051492
11. Takahara S, Maruo A, Takayama H, Harada T, Continuous local antibiotics perfusion therapy for acute deep infections after open fractures: Case Rep Orthop, 2022; 2022; 2563939
12. Kosugi K, Zenke Y, Sato N, Potential of continuous local antibiotic perfusion therapy for fracture-related infections: Infect Dis Ther, 2022; 11(4); 1741-55
13. Zenke Y, Motojima Y, Ando K, DAIR in treating chronic PJI after total knee arthroplasty using continuous local antibiotic perfusion therapy: A case series study: BMC Musculoskelet Disord, 2024; 25(1); 36
14. Choe H, Maruo A, Hieda Y, Novel local antifungal treatment for fungal periprosthetic joint infection with continuous local antibiotic perfusion: A surgical technique: Arthroplast Today, 2023; 24; 101245
15. Gramlich Y, Johnson T, Kemmerer M, Salvage procedure for chronic periprosthetic knee infection: the application of DAIR results in better remission rates and infection-free survivorship when used with topical degradable calcium-based antibiotics: Knee Surg Sports Traumatol Arthrosc, 2020; 28(9); 2823-34
16. Doski S, Sebastiao A, Thayaparan P, The investigation and management of peri-prosthetic joint infection after total knee arthroplasty: An update based on the latest British Orthopaedic Association standard and speciality standard guidelines: Cureus, 2024; 16(11); e73315
17. Rimke C, Enz A, Bail HJ, Evaluation of the standard procedure for the treatment of periprosthetic joint infections (PJI) in Germany – results of a survey within the EndoCert initiative: BMC Musculoskelet Disord, 2020; 21(1); 694
18. Wirries N, Tuecking LR, Skutek M, One-stage implant-retaining revision for simultaneous bilateral infected total knee arthroplasty: A report of a rare case: Case Rep Orthop, 2021; 2021; 8846198
19. Pina M, Gaukhman AD, Hayden B, Smith EL, Three concurrent periprosthetic joint infections: A case report and literature review: Hip Pelvis, 2019; 31(1); 57-62
20. Roerdink RL, Douw CM, Leenders AC, Bilateral periprosthetic joint infection with Ureaplasma urealyticum in an immunocompromised patient: Infection, 2016; 44(6); 807-10
21. Balkhair A, Al Maskari S, Ibrahim S, Brucella periprosthetic joint infection involving bilateral knees with negative synovial fluid alpha-defensin: Case Rep Infect Dis, 2019; 2019; 9423946
22. Matsumoto T, Ishida K, Tsumura N, Treatment of 50 deep infections after total knee arthroplasty: Orthopedics, 2015; 38(6); e529-35
23. Nakano N, Matsumoto T, Ishida K, Factors influencing the outcome of deep infection following total knee arthroplasty: Knee, 2015; 22(4); 328-32
24. Tsukayama DT, Goldberg VM, Kyle R, Diagnosis and management of infection after total knee arthroplasty: J Bone Joint Surg Am, 2003; 85-A(Suppl 1); S75-80
25. Kaminski A, Citak M, Schildhauer TA, Fehmer T, Success rates for initial eradication of peri-prosthetic knee infection treated with a two-stage procedure: Ortop Traumatol Rehabil, 2014; 16(1); 11-16
26. Ferguson J, Diefenbeck M, McNally M, Ceramic biocomposites as biodegradable antibiotic carriers in the treatment of bone infections: J Bone Jt Infect, 2017; 2(1); 38-51
27. Sandoe JA, Wysome J, West AP, Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilms: J Antimicrob Chemother, 2006; 57(4); 767-70
28. Mottola C, Matias CS, Mendes JJ: BMC Microbiol, 2016; 16(1); 119
Figures
Figure 1. Preoperative radiographs showing no evidence of radiolucency.
Figure 2. Postoperative radiograph (A) and diagram of the continuous local antibiotic perfusion (B).
Figure 3. Radiographs at the time of discharge showing (A) frontal image of the right knee; (B) lateral image of the right maximum extension; (C) lateral image of the right knee in maximum flexion; (D) lateral image of the left maximum extension; (E) lateral image of the left maximum flexion; and (F) frontal image of the left knee.
Figure 4. The C-reactive protein (CRP*) levels, white blood cell (WBC**) counts, and intervention (antibiotics and surgery) are shown. In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






